TheStreet Quant Ratings rates Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.48 on last trade day and at the end of the day closed at $8.17. Company price to sales ratio in past twelve months was calculated as 33.27 and price to cash ratio as 5.15. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 0.49%.
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target upped by Leerink Swann from $29.00 to $45.00 in a research note issued to investors on Monday, Analyst Ratings.Net reports. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares advanced 7.11% in last trading session and ended the day on $40.85. ENTA return on equity ratio is recorded as -12.20% and its return on assets is -11.60%.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Agenus Inc (NASDAQ:AGEN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the 2009 Equity Incentive Plan. Agenus Inc (NASDAQ:AGEN) shares moved up 5.88%in last trading session and was closed at $4.32, while trading in range of $4.16 – $4.53. Agenus Inc (NASDAQ:AGEN) year to date (YTD) performance is 63.64%.
Ohr Pharmaceutical currently has a Zacks Rank #2 (Buy). OHR Pharmaceutical Inc (NASDAQ:OHRP) weekly performance is 10.83%. On last trading day company shares ended up $19.65. OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is 59.41%. Analysts mean target price for the company is $21.00.
Leave a Reply